China NT Pharma Group Co Ltd (1011.HK)
1011.HK on Hong Kong Stock
1.93HKD
2:44am BST
1.93HKD
2:44am BST
Change (% chg)
HK$-0.02 (-1.03%)
HK$-0.02 (-1.03%)
Prev Close
HK$1.95
HK$1.95
Open
HK$1.95
HK$1.95
Day's High
HK$1.95
HK$1.95
Day's Low
HK$1.92
HK$1.92
Volume
328,500
328,500
Avg. Vol
3,226,135
3,226,135
52-wk High
HK$2.48
HK$2.48
52-wk Low
HK$1.61
HK$1.61
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- ownership
- filings
- deals
- private equity
- third-party document and information retrieval
- estimates
- fundamentals
- economics
- events
- news
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
| Name | Age | Since | Current Position |
|---|---|---|---|
Tit Ng |
51 | Executive Chairman of the Board, Chief Executive Officer | |
Fei Wang |
41 | 2018 | Chief Financial Officer |
Baoming Ge |
49 | General Manager of Corporate Development and Product Research and Development Centre | |
Yu Chin |
51 | 2015 | Executive Director |
Weizhong Wu |
45 | 2015 | Executive Director |
- BRIEF-Pfenex And NT Pharma Enter Into A Development And License Agreement For Pfenex's PF708 Therapeutic Equivalent Candidate To Forteo
- BRIEF-China NT Pharma Group Co Appoints Wang Fei As CFO
- BRIEF-China Nt Pharma Group Co Fy Net Profit Attributable RMB 165.2 Mln VS RMB 116.2 Mln
- BRIEF-China Nt Pharma Group Co Says Co To Cease Libod Sales & Promotion From Dec. 31, 2017